Biotechnology
Compare Stocks
4 / 10Stock Comparison
OSRH vs DBVT vs ALKS vs HCWB
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
Biotechnology
Biotechnology
OSRH vs DBVT vs ALKS vs HCWB — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Biotechnology |
| Market Cap | $3M | $1712.35T | $5.90B | $668K |
| Revenue (TTM) | $3M | $0.00 | $1.56B | $54K |
| Net Income (TTM) | $-21M | $-168M | $153M | $-8M |
| Gross Margin | 18.3% | — | 65.4% | -300.7% |
| Operating Margin | -5.6% | — | 12.3% | -215.1% |
| Forward P/E | — | — | 24.8x | — |
| Total Debt | $2M | $22M | $70M | $7M |
| Cash & Equiv. | $66K | $194M | $1.12B | $2M |
OSRH vs DBVT vs ALKS vs HCWB — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jan 25 | May 26 | Return |
|---|---|---|---|
| OSR Holdings, Inc. (OSRH) | 100 | 6.1 | -93.9% |
| DBV Technologies S.… (DBVT) | 100 | 473.7 | +373.7% |
| Alkermes plc (ALKS) | 100 | 112.3 | +12.3% |
| HCW Biologics Inc. (HCWB) | 100 | 2.9 | -97.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: OSRH vs DBVT vs ALKS vs HCWB
Each card shows where this stock fits in a portfolio — not just who wins on paper.
OSRH plays a supporting role in this comparison — it may shine differently against other peers.
DBVT is the #2 pick in this set and the best alternative if income & stability is your priority.
- Dividend streak 0 yrs, beta 1.26
- +110.4% vs HCWB's -95.4%
ALKS carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth -5.2%, EPS growth -34.1%, 3Y rev CAGR 9.9%
- -11.0% 10Y total return vs DBVT's -87.0%
- Lower volatility, beta 1.06, Low D/E 3.8%, current ratio 3.55x
- Beta 1.06, current ratio 3.55x
HCWB lags the leaders in this set but could rank higher in a more targeted comparison.
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | -5.2% revenue growth vs OSRH's -159.0% | |
| Quality / Margins | 9.8% margin vs HCWB's -146.8% | |
| Stability / Safety | Beta 1.06 vs OSRH's 1.90 | |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | +110.4% vs HCWB's -95.4% | |
| Efficiency (ROA) | 5.4% ROA vs DBVT's -89.0% |
OSRH vs DBVT vs ALKS vs HCWB — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
Segment breakdown not available.
OSRH vs DBVT vs ALKS vs HCWB — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
ALKS leads in 3 of 6 categories
OSRH leads 0 • DBVT leads 0 • HCWB leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
ALKS leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ALKS and DBVT operate at a comparable scale, with $1.6B and $0 in trailing revenue. ALKS is the more profitable business, keeping 9.8% of every revenue dollar as net income compared to HCWB's -146.8%. On growth, ALKS holds the edge at +28.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $3M | $0 | $1.6B | $54,231 |
| EBITDAEarnings before interest/tax | -$12M | -$112M | $212M | -$11M |
| Net IncomeAfter-tax profit | -$21M | -$168M | $153M | -$8M |
| Free Cash FlowCash after capex | -$4M | -$151M | $392M | -$13M |
| Gross MarginGross profit ÷ Revenue | +18.3% | — | +65.4% | -3.0% |
| Operating MarginEBIT ÷ Revenue | -5.6% | — | +12.3% | -215.1% |
| Net MarginNet income ÷ Revenue | -8.2% | — | +9.8% | -146.8% |
| FCF MarginFCF ÷ Revenue | -149.0% | — | +25.1% | -246.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — | +28.2% | -93.2% |
| EPS Growth (YoY)Latest quarter vs prior year | -11.4% | +91.5% | -4.1% | -21.1% |
Valuation Metrics
Evenly matched — OSRH and ALKS and HCWB each lead in 1 of 3 comparable metrics.
Valuation Metrics
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $3M | $1712.35T | $5.9B | $668,096 |
| Enterprise ValueMkt cap + debt − cash | $5M | $1712.35T | $4.9B | $6M |
| Trailing P/EPrice ÷ TTM EPS | -1.28x | -0.76x | 24.76x | -0.03x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | 17.25x | — |
| Price / SalesMarket cap ÷ Revenue | — | — | 4.00x | 12.32x |
| Price / BookPrice ÷ Book value/share | — | 0.66x | 3.28x | 0.24x |
| Price / FCFMarket cap ÷ FCF | — | — | 12.28x | — |
Profitability & Efficiency
ALKS leads this category, winning 8 of 9 comparable metrics.
Profitability & Efficiency
ALKS delivers a 8.8% return on equity — every $100 of shareholder capital generates $9 in annual profit, vs $-3 for HCWB. ALKS carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to HCWB's 2.46x. On the Piotroski fundamental quality scale (0–9), ALKS scores 7/9 vs HCWB's 3/9, reflecting strong financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | -15.5% | -130.2% | +8.8% | -2.9% |
| ROA (TTM)Return on assets | -11.7% | -89.0% | +5.4% | -30.3% |
| ROICReturn on invested capital | -19.1% | — | +18.9% | -171.1% |
| ROCEReturn on capital employed | -23.4% | -145.7% | +14.2% | -5.5% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 4 | 7 | 3 |
| Debt / EquityFinancial leverage | — | 0.13x | 0.04x | 2.46x |
| Net DebtTotal debt minus cash | $2M | -$172M | -$1.0B | $5M |
| Cash & Equiv.Liquid assets | $66,135 | $194M | $1.1B | $2M |
| Total DebtShort + long-term debt | $2M | $22M | $70M | $7M |
| Interest CoverageEBIT ÷ Interest expense | -152.34x | -189.82x | 32.30x | -8.05x |
Total Returns (Dividends Reinvested)
Evenly matched — DBVT and ALKS each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ALKS five years ago would be worth $16,091 today (with dividends reinvested), compared to $13 for HCWB. Over the past 12 months, DBVT leads with a +110.4% total return vs HCWB's -95.4%. The 3-year compound annual growth rate (CAGR) favors DBVT at 6.2% vs HCWB's -82.2% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | +17.3% | +4.9% | +25.3% | -71.4% |
| 1-Year ReturnPast 12 months | -45.6% | +110.4% | +16.5% | -95.4% |
| 3-Year ReturnCumulative with dividends | -93.9% | +19.7% | +14.5% | -99.4% |
| 5-Year ReturnCumulative with dividends | -93.9% | -69.1% | +60.9% | -99.9% |
| 10-Year ReturnCumulative with dividends | -93.9% | -87.0% | -11.0% | -99.9% |
| CAGR (3Y)Annualised 3-year return | -60.7% | +6.2% | +4.6% | -82.2% |
Risk & Volatility
ALKS leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
ALKS is the less volatile stock with a 1.06 beta — it tends to amplify market swings less than OSRH's 1.90 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ALKS currently trades 96.7% from its 52-week high vs HCWB's 1.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.90x | 1.26x | 1.06x | 1.54x |
| 52-Week HighHighest price in past year | $1.79 | $26.18 | $36.60 | $17.80 |
| 52-Week LowLowest price in past year | $0.38 | $7.53 | $25.17 | $0.25 |
| % of 52W HighCurrent price vs 52-week peak | +38.6% | +76.3% | +96.7% | +1.8% |
| RSI (14)Momentum oscillator 0–100 | 50.6 | 48.1 | 60.2 | 41.6 |
| Avg Volume (50D)Average daily shares traded | 7.3M | 252K | 2.3M | 10.8M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: DBVT as "Buy", ALKS as "Buy". Consensus price targets imply 131.8% upside for DBVT (target: $46) vs 24.3% for ALKS (target: $44).
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy | — |
| Price TargetConsensus 12-month target | — | $46.33 | $44.00 | — |
| # AnalystsCovering analysts | — | 15 | 28 | — |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | 0 | 0 | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +0.5% | 0.0% |
ALKS leads in 3 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 2 categories are tied.
OSRH vs DBVT vs ALKS vs HCWB: Key Questions Answered
8 questions · data-driven answers · updated daily
01Is OSRH or DBVT or ALKS or HCWB a better buy right now?
For growth investors, Alkermes plc (ALKS) is the stronger pick with -5.
2% revenue growth year-over-year, versus -97. 9% for HCW Biologics Inc. (HCWB). Alkermes plc (ALKS) offers the better valuation at 24. 8x trailing P/E, making it the more compelling value choice. Analysts rate DBV Technologies S. A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — OSRH or DBVT or ALKS or HCWB?
Over the past 5 years, Alkermes plc (ALKS) delivered a total return of +60.
9%, compared to -99. 9% for HCW Biologics Inc. (HCWB). Over 10 years, the gap is even starker: ALKS returned -11. 0% versus HCWB's -99. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — OSRH or DBVT or ALKS or HCWB?
By beta (market sensitivity over 5 years), Alkermes plc (ALKS) is the lower-risk stock at 1.
06β versus OSR Holdings, Inc. 's 1. 90β — meaning OSRH is approximately 80% more volatile than ALKS relative to the S&P 500. On balance sheet safety, Alkermes plc (ALKS) carries a lower debt/equity ratio of 4% versus 2% for HCW Biologics Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — OSRH or DBVT or ALKS or HCWB?
By revenue growth (latest reported year), Alkermes plc (ALKS) is pulling ahead at -5.
2% versus -97. 9% for HCW Biologics Inc. (HCWB). On earnings-per-share growth, the picture is similar: Alkermes plc grew EPS -34. 1% year-over-year, compared to -1280. 5% for HCW Biologics Inc.. Over a 3-year CAGR, ALKS leads at 9. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — OSRH or DBVT or ALKS or HCWB?
Alkermes plc (ALKS) is the more profitable company, earning 16.
4% net margin versus -146. 8% for HCW Biologics Inc. — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALKS leads at 17. 2% versus -207. 6% for HCWB. At the gross margin level — before operating expenses — ALKS leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — OSRH or DBVT or ALKS or HCWB?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is OSRH or DBVT or ALKS or HCWB better for a retirement portfolio?
For long-horizon retirement investors, Alkermes plc (ALKS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.
06)). OSR Holdings, Inc. (OSRH) carries a higher beta of 1. 90 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ALKS: -11. 0%, OSRH: -93. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between OSRH and DBVT and ALKS and HCWB?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.